International Stem Cell Corp.
0.1500+0.00 (+0%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCQB · ISCO · USD
Key Stats
Market Cap
1.20MP/E (TTM)
-Basic EPS (TTM)
-0.04Dividend Yield
0%Recent Filings
8-K
CEO loan maturity extended
International Stem Cell Corporation extended a $2,500,000 promissory note to CEO Dr. Andrey Semechkin until September 15, 2026, carrying forward $799,064.44 in fixed accrued interest from the original note. The principal accrues interest at 5.5% annually, with prepayment allowed anytime without penalty. This insider extension provides breathing room for operations. Yet liquidity remains tight.
10-Q
Q2 FY2025 results
International Stem Cell Corporation posted Q2 product sales of $2.4M, up 5% y/y from $2.3M, driven by a 9% y/y rise in biomedical segment revenue to $2.3M while anti-aging skin care dipped 32% y/y to $0.1M; gross margin held steady at 62%, edging up 1 point y/y amid sales mix shifts. Operating income climbed 12% y/y to $0.2M, buoyed by controlled cost increases, though YTD swung to a $0.05M operating loss from a $0.03M loss last year due to higher R&D spending on Parkinson's trials. Diluted EPS of $0.01 matched y/y, confirmed against 8M weighted shares with no anti-dilution flags. Cash fell to $0.9M from $1.2M year-start, with operating cash use at $0.07M and $0.2M related-party debt paydown; free cash flow not disclosed in the 10-Q. One customer dominated 52% of sales. Regulatory hurdles in stem cell approvals loom large.
10-Q
Q1 FY2025 results
International Stem Cell held product sales steady at $2.1M for Q1 FY2025 ended March 31, 2025, flat year-over-year yet up slightly quarter-over-quarter from derived figures, with biomedical media and cells driving 94% of revenue while anti-aging skin care dipped to $134K from $206K. Gross margins slipped to 53% from 58% y/y, pressured by a sales mix shift in biomedical and lower skin care volume, leading to an operating loss of $215K versus $178K last year; net loss widened to $256K, or $(0.03) per diluted share on 8M shares, matching y/y but with the gap to operating loss tied to $41K interest expense, mainly related-party. Cash climbed to $1.5M, bolstered by $227K operating cash flow—flipping from a $193K y/y use—while free cash flow stood at $222K after minimal $5K capex; related-party debt of $3.4M at 5.5% matures September 2025, with $663K in lease liabilities through 2026. No M&A or non-GAAP metrics disclosed in the 10-Q. One customer dominated 56% of sales. Substantial doubt lingers on going concern amid funding needs.
10-K
FY2024 results
International Stem Cell Corporation's 10-K filing for the fiscal year ended December 31, 2024, lacks detailed financial statements and quarterly breakdowns, limiting insight into annual topline or profitability metrics. Without disclosed figures for revenue, net loss, or EPS, the annual context remains opaque, and Q4 performance cannot be assessed for momentum or sequential trends. Key drivers, segment contributions, and liquidity posture are not detailed in the provided sections. No capital allocation actions like buybacks or dividends are mentioned for the year or Q4. The filing offers no guidance for 2025. Regulatory hurdles in stem cell research pose a persistent risk to future momentum.
10-Q
Q3 FY2024 results
International Stem Cell Corporation posted Q3 product sales of $2.2M, up 10% y/y from $2.0M, driven by stronger biomedical media and cell demand, though gross margins slipped to 55% from 60% on inventory adjustments and scrap. Operating loss narrowed to $90K from $97K y/y, with R&D up 21% to $187K on personnel and lab costs, yet overall expenses held steady. YTD sales climbed 13% to $6.6M, but net loss of $220K reflects no repeat of last year's $663K employee retention credit; EPS of -$0.03 aligns with 8M diluted shares. Cash dipped to $1.3M after $87K operating inflow and $200K debt repayment, leaving $2.7M related-party note at 5.5% due September 2025. Biomedical segment, over 90% of revenue, powers growth. Still, customer concentration risks loom large.
IPO
Employees
Sector
Industry
BCLI
Brainstorm Cell Therapeutics In
0.68-0.01
BRTX
BioRestorative Therapies, Inc.
1.56-0.09
BSEM
BioStem Technologies, Inc.
4.66+0.16
CCEL
Cryo-Cell International, Inc.
4.40-0.11
ICCC
ImmuCell Corporation
6.03-0.20
ICU
SeaStar Medical Holding Corpora
0.57-0.00
NSTM
NovelStem International Corp.
0.02+0.00
STEK
Stemtech Corp.
0.00-0.00
STME
Stimcell Energetics, Inc.
0.44+0.03
YBGJ
Yubo International Biotech Limi
0.01+0.00